A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

This study is testing a new dosing schedule for sacituzumab govitecan — a targeted antibody-drug treatment — to find out if a different dose and timing can be just as effective but with fewer side effects in people with advanced triple-negative breast cancer (TNBC). **You may be eligible if...** - You are 18 or older with confirmed triple-negative breast cancer that has spread or cannot be removed surgically - Phase 1: You have received at least one prior chemotherapy for advanced TNBC - Phase 2: You have not received prior treatment for advanced TNBC, AND your tumour's PD-L1 score (CPS) is below 10 (meaning immunotherapy alone is unlikely to be effective) **You may NOT be eligible if...** - You have untreated or symptomatic brain metastases - You have active, serious autoimmune conditions - You have previously received sacituzumab govitecan or similar antibody-drug treatments - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.